Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425755 | 0.84 | CASP3 (0.40) | GCGRMAPK14CDK5CDK5R1CDC7 | |
| SCHEMBL5567654 | 0.83 | PDE3B (0.44) | MMP13MMP2MMP14GSK3BNPC1 | |
| SCHEMBL3424712 | 0.82 | PKN1 (0.51) | PKN1PKN2MMP13MMP2MMP14 | |
| SCHEMBL5571078 | 0.82 | CHEK1 (0.41) | MMP13MMP2MMP14CDK5CDK5R1 | |
| SCHEMBL1750300 | 0.81 | HSD17B10 (0.51) | CDK5CDK5R1GSK3BNPC1MAPT | |
| SCHEMBL3425296 | 0.80 | MAPK1 (0.52) | PKN1PKN2MMP13MMP2MMP14 | |
| SCHEMBL3424912 | 0.80 | CHEK1 (0.55) | — | |
| SCHEMBL1750916 | 0.79 | GSK3A (0.54) | GSK3BNPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL1749943 | 0.78 | CDK5 (0.55) | CDK5CDK5R1GSK3BNPC1MAPT | |
| SCHEMBL1752294 | 0.77 | CDK5 (0.54) | MAPK14CDK5CDK5R1CDC7ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | claimed |
| EP-1753743-B1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-03-04 | — | — | EP | disclosed |
| EP-1753743-B1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| EP-1753743-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005111018-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111018-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | PKN1 29/4885PKN2 8/4885MMP13 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.